Red White & Bloom Brands Past Earnings Performance
Past criteria checks 0/6
Red White & Bloom Brands's earnings have been declining at an average annual rate of -66.3%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 59.5% per year.
Key information
-66.3%
Earnings growth rate
-4.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 59.5% |
| Return on equity | n/a |
| Net Margin | -266.2% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Take Care Before Diving Into The Deep End On Red White & Bloom Brands Inc. (CSE:RWB)
Apr 19
Slammed 30% Red White & Bloom Brands Inc. (CSE:RWB) Screens Well Here But There Might Be A Catch
Dec 21Little Excitement Around Red White & Bloom Brands Inc.'s (CSE:RWB) Revenues As Shares Take 26% Pounding
Apr 17Lacklustre Performance Is Driving Red White & Bloom Brands Inc.'s (CSE:RWB) 26% Price Drop
Apr 17Red White & Bloom Brands' (CSE:RWB) Promising Earnings May Rest On Soft Foundations
Aug 10Is Red White & Bloom Brands (CSE:RWB) Using Debt In A Risky Way?
Sep 03Revenue & Expenses BreakdownBeta
How Red White & Bloom Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 86 | -228 | 36 | 0 |
| 30 Jun 23 | 91 | -230 | 35 | 0 |
| 31 Mar 23 | 96 | -237 | 38 | 0 |
| 31 Dec 22 | 97 | -239 | 38 | 0 |
| 30 Sep 22 | 83 | -11 | 27 | 0 |
| 30 Jun 22 | 69 | -7 | 38 | 0 |
| 31 Mar 22 | 53 | 7 | 34 | 0 |
| 31 Dec 21 | 37 | -39 | 35 | 0 |
| 30 Sep 21 | 46 | -42 | 33 | 0 |
| 30 Jun 21 | 41 | -48 | 27 | 0 |
| 31 Mar 21 | 31 | -70 | 22 | 0 |
| 31 Dec 20 | 19 | -10 | 15 | 0 |
| 30 Sep 20 | 8 | -35 | 18 | 0 |
| 30 Jun 20 | 2 | -26 | 9 | 0 |
| 31 Mar 20 | 0 | -8 | 11 | 0 |
| 31 Dec 19 | 0 | -13 | 8 | 0 |
| 30 Jun 19 | 0 | -8 | 9 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
Quality Earnings: RWB is currently unprofitable.
Growing Profit Margin: RWB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RWB is unprofitable, and losses have increased over the past 5 years at a rate of 66.3% per year.
Accelerating Growth: Unable to compare RWB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RWB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: RWB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.